Marginal Zone Lymphoma Market Analysis 2034: Industry Trends, Market Size, and Emerging Therapeutic Developments - DelveInsight

DelveInsight's "Marginal Zone Lymphoma Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Marginal Zone Lymphoma, historical and forecasted epidemiology as well as the Marginal Zone Lymphoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Marginal Zone Lymphoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Marginal Zone Lymphoma Market Forecast
https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Some of the key facts of the Marginal Zone Lymphoma Market Report:
• The Marginal Zone Lymphoma market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In December 2025, The U.S. Food and Drug Administration (FDA) has approved Breyanzi® (lisocabtagene maraleucel; liso-cel) for treating adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) who have undergone at least two prior systemic therapies. Breyanzi is a CD19-targeted, genetically engineered autologous T-cell immunotherapy. This approval is supported by results from the MZL cohort of the open-label, single-arm Phase 2 TRANSCEND FL trial (ClinicalTrials.gov Identifier: NCT04245839), which assessed liso-cel in adults with R/R MZL who had received two or more prior systemic therapies-including an anti-CD20 antibody and an alkylating agent-or had relapsed following hematopoietic stem cell transplantation. Eligible patients also required an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• In December 2025, Genmab has launched an open-label, multicenter clinical trial to evaluate the safety and preliminary efficacy of epcoritamab (EPKINLYTM) in Japanese patients with relapsed, progressive, or refractory B-cell lymphomas, as well as those who achieved partial or complete responses after previous standard therapies. The study is designed in two parts: a Phase I dose-escalation segment, followed by a Phase II expansion phase.
• In August 2025, The decision specifically targets adults with relapsed or refractory MZL who have undergone at least two prior systemic therapies. Breyanzi will now undergo an expedited review, potentially accelerating patient access, with a target decision date of December 5 this year. BMS' application is supported by data from the primary analysis of the MZL cohort in the Phase 2 TRANSCEND FL study, which showed clinically significant benefits for patients treated with Breyanzi.
• In August 2025, The FDA has granted priority review to a supplemental biologics license application (sBLA) for lisocabtagene maraleucel (liso-cel; Breyanzi), seeking approval for treating adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least two prior systemic therapies. The application is supported by results from the MZL cohort of the Phase 2 TRANSCEND FL trial (NCT04245839). Data presented at the 2025 International Conference on Malignant Lymphoma showed that among 66 efficacy-evaluable patients, the overall response rate (ORR) was 95.5% (95% CI, 87.3%-99.1%; 1-sided P < .0001), including a complete response (CR) rate of 62.1% (95% CI, 49.3%-73.8%; 1-sided P < .0001).
• In June 2025, ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader in antibody-drug conjugates (ADCs), announced that updated data from a Phase 2 multicenter investigator-initiated trial (IIT) of ZYNLONTA® for relapsed/refractory marginal zone lymphoma (r/r MZL) will be presented in a poster session at the 18th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland, on Friday, June 20. The data will be available online starting Wednesday, June 18, at 8:30 a.m. CEST. The single-arm, open-label study is led by Izidore S. Lossos, MD, Chief of the Division of Hematology Lymphoma Section at Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine.
• In June 2025, A rituximab and ibrutinib combination therapy demonstrates potential in treating marginal zone lymphoma (MZL), according to a poster presentation at ICML 2025. Currently, no standard first-line therapies exist for MZL patients. Previous studies have shown that BTK inhibitors offer a favorable risk-benefit profile in relapsed MZL, regardless of subtype, including splenic (SMZL) and nodal (NMZL) marginal zone lymphoma. The phase II IELSG47/MALIBU trial evaluated the efficacy and safety of combining rituximab with ibrutinib, both BTK inhibitors, for the treatment of MZL, highlighting encouraging clinical outcomes.
• In February 2025, Lisocabtagene maraleucel (Liso-cel; Breyanzi) demonstrated a statistically significant and clinically meaningful overall response rate (ORR) in adult patients with relapsed or refractory marginal zone lymphoma (MZL), achieving the primary endpoint for the MZL cohort in the Phase 2 TRANSCEND FL trial (NCT04245839).
• In February 2025, Bristol Myers Squibb (BMS) announced that its multi-center Phase II TRANSCEND FL trial has achieved the primary endpoint in the marginal zone lymphoma (MZL) cohort. The study evaluates Breyanzi, a CD19-targeted CAR T cell therapy, in adult patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (NHL).
• In January 2025, Verismo Therapeutics, a clinical-stage CAR T company specializing in KIR-CAR platform technology, announced the dosing of the first patient in its CELESTIAL-301 Phase 1 clinical trial. The infusion took place at the Sarah Cannon Research Institute (SCRI) at Colorado Blood Cancer Institute (CBCI) in Denver, Colorado. The CELESTIAL-301 trial is designed to evaluate the safety, tolerability, and preliminary efficacy of SynKIRTM-310 in patients with relapsed/refractory (r/r) B-cell Non-Hodgkin Lymphomas (B-cell NHL), including Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), and Marginal Zone Lymphoma (MZL). This Phase 1 multicenter trial is enrolling patients who have previously undergone CAR T therapy but relapsed or became refractory, as well as those who have never received CAR T therapy.
• In August 2024, The UK National Institute for Health and Care Excellence (NICE) has endorsed BeiGene's Zanubrutinib (Brukinsa) for treating marginal zone lymphoma (MZL), a form of blood cancer, within the National Health Service (NHS). This approval introduces a new treatment option for patients in England, with the potential to slow cancer progression and reduce the need for additional chemotherapy.
• In 2023, the United States recorded the highest number of marginal zone lymphoma (MZL) incidence cases among the 7MM, exceeding 8,000 cases. This number is projected to grow throughout the forecast period.
• In gender-specific Marginal Zone Lymphoma incidence cases, males represent the predominant group.
• In 2023, MALT lymphoma accounted for the largest proportion of incident cases in the US, comprising approximately 70%, followed by SMZL and NMZL.
• In the US in 2023, stage-specific incidence of Marginal Zone Lymphoma was highest for Stage III-IV cases, followed by Stage I and Stage II.
• YESCARTA and BREYANZI are gaining recognition as promising treatments for MZL, with BREYANZI anticipated to receive approval for third-line (3L+) MZL cases by 2026.
• Key Marginal Zone Lymphoma Companies: Bristol-Myers Squibb, TG Therapeutics, Gilead Sciences, AstraZeneca, Nordic Nanovector, Christian Buske, AbbVie, Pharmacyclics LLC, Hutchison Medipharma, Beigene, Incyte Corporation, Enterome, and others
• Key Marginal Zone Lymphoma Therapies: REVLIMID (lenalidomide), UKONIQ (umbralisib), BREYANZI (lisocabtagene maraleucel), Yescarta, Calquence, Betalutin, Obinutuzumab, Rituximab, Ibrutinib, HMPL-689, Zanubrutinib, tafasitamab, EO2463, and others
• The Marginal Zone Lymphoma epidemiology based on gender analyzed that a higher number of males were affected by this disease, i.e., ~54%of the total incident MZL population in the United States, which is equivalent to ~4,300 cases. In comparison to this, for females, the number of cases observed was ~3,700 in 2022.
• The Marginal Zone Lymphoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Marginal Zone Lymphoma pipeline products will significantly revolutionize the Marginal Zone Lymphoma market dynamics.

Marginal Zone Lymphoma Overview
Marginal Zone Lymphoma (MZL) is a type of non-Hodgkin lymphoma, a cancer that originates in white blood cells called lymphocytes. MZL specifically affects a subset of these lymphocytes known as marginal zone B-cells, which are found at the edges, or margins, of lymphoid tissues like the lymph nodes, spleen, and mucosa-associated lymphoid tissue (MALT) such as the stomach, salivary glands, or other organs.

Get a Free sample for the Marginal Zone Lymphoma Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/marginal-zone-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Marginal Zone Lymphoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Marginal Zone Lymphoma Epidemiology Segmentation:
The Marginal Zone Lymphoma market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Marginal Zone Lymphoma
• Prevalent Cases of Marginal Zone Lymphoma by severity
• Gender-specific Prevalence of Marginal Zone Lymphoma
• Diagnosed Cases of Episodic and Chronic Marginal Zone Lymphoma

Download the report to understand which factors are driving Marginal Zone Lymphoma epidemiology trends @ Marginal Zone Lymphoma Epidemiology Forecast
https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Marginal Zone Lymphoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Marginal Zone Lymphoma market or expected to get launched during the study period. The analysis covers Marginal Zone Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Marginal Zone Lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Marginal Zone Lymphoma Therapies and Key Companies
• REVLIMID (lenalidomide): Bristol-Myers Squibb
• UKONIQ (umbralisib): TG Therapeutics
• BREYANZI (lisocabtagene maraleucel): Bristol Myers Squibb
• Yescarta: Gilead Sciences
• Calquence: AstraZeneca
• Betalutin: Nordic Nanovector
• Obinutuzumab: Christian Buske
• Rituximab: AbbVie
• Ibrutinib: Pharmacyclics LLC
• HMPL-689: Hutchison Medipharma
• Zanubrutinib: Beigene
• tafasitamab: Incyte Corporation
• EO2463: Enterome

Discover more about therapies set to grab major Marginal Zone Lymphoma market share @ Marginal Zone Lymphoma Treatment Landscape
https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Marginal Zone Lymphoma Market Drivers
• Growing demand for targeted therapies: The development and adoption of targeted treatments, including BTK inhibitors such as zanubrutinib, are expanding therapeutic options for patients with relapsed or refractory MZL.
• Rising focus on subtype-specific treatments: Increasing recognition of the biological and clinical differences among extranodal, splenic, and nodal MZL is encouraging the development of more personalized treatment approaches.
• High unmet need in relapsed/refractory disease: Limited treatment choices following relapse and the need for effective, well-tolerated, and convenient therapies are creating opportunities for innovative drugs.
• Expansion of clinical research: Greater emphasis on MZL-specific clinical trials and disease-relevant endpoints is supporting the development of new therapies and potentially strengthening the treatment pipeline.
• Increasing disease recognition and diagnosis: MZL represents a meaningful proportion of non-Hodgkin lymphomas, while improvements in pathological diagnosis and disease classification may contribute to greater identification of cases.

Marginal Zone Lymphoma Market Barriers
• Disease rarity and heterogeneity: MZL is relatively uncommon and comprises multiple distinct subtypes, making patient recruitment and the development of broadly applicable therapies challenging.
• Limited MZL-specific clinical evidence: Many historical treatment approaches have been extrapolated from follicular lymphoma studies, with relatively few trials specifically designed and adequately powered for MZL.
• Limited treatment options after relapse: Patients with relapsed or refractory disease continue to face a restricted range of effective therapies, particularly those who cannot tolerate chemotherapy.
• Diagnostic complexity: Differences in presentation, biology, and treatment response across MZL subtypes can complicate diagnosis, patient stratification, and evaluation of therapeutic outcomes.
• Treatment-related toxicity and tolerability concerns: Chemotherapy-based regimens can increase toxicity and frailty risks, particularly among older patients, creating demand for safer and more convenient treatment alternatives.

Scope of the Marginal Zone Lymphoma Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Marginal Zone Lymphoma Companies: Bristol-Myers Squibb, TG Therapeutics, Gilead Sciences, AstraZeneca, Nordic Nanovector, Christian Buske, AbbVie, Pharmacyclics LLC, Hutchison Medipharma, Beigene, Incyte Corporation, Enterome, and others
• Key Marginal Zone Lymphoma Therapies: REVLIMID (lenalidomide), UKONIQ (umbralisib), BREYANZI (lisocabtagene maraleucel), Yescarta, Calquence, Betalutin, Obinutuzumab, Rituximab, Ibrutinib, HMPL-689, Zanubrutinib, tafasitamab, EO2463, and others
• Marginal Zone Lymphoma Therapeutic Assessment: Marginal Zone Lymphoma current marketed and Marginal Zone Lymphoma emerging therapies
• Marginal Zone Lymphoma Market Dynamics: Marginal Zone Lymphoma market drivers and Marginal Zone Lymphoma market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Marginal Zone Lymphoma Unmet Needs, KOL's views, Analyst's views, Marginal Zone Lymphoma Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.